IPHA News
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the...
Business Wire
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor...
Business Wire
Innate Pharma Announces Conference Call and Webcast
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer...
Business Wire
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.read more...
Benzinga
Innate Pharma Lands Major Lacutamab Lifeline as Phase 3 Push Accelerates
Innate Pharma (NASDAQ:IPHA) is entering a potentially pivotal new chapter after announcing plans to advance lacutamab toward the TELLOMAK-3 Phase 3 study following its strategic partnership with Sobi. The deal provides a significant financial catalyst at a critical point in development, with Innate expecting a $75 million upfront payment upon closing and additional near-term development milestones. The company says the proceeds are intended to support TELLOMAK-3 and a planned filing for accelerated approval of lacutamab in Sézary syndrome, while extending its projected cash runway through the third quarter of 2027.
24-7 Market News
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma PR Newswire STOCKHOLM, Aug. 10, 2026 STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish OrphanBiovitrum AB (publ...
PR Newswire
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate...
Business Wire
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell...
Business Wire
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel...
Business Wire
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and...
Business Wire